Comparison of Two Different Injectable Contraceptive Methods: Depo-medroxy Progesterone Acetate (DMPA) and Cyclofem

Firoozeh Veisi; M.D., Maryam Zangeneh; M.D.

Department of Obstetrics & Gynecology, High Risk Pregnancy Research Center, Kermanshah University of Medical Science, Kermanshah, Iran

Received December 2012; revised and accepted February 2013

Abstract
Objective: To compare side effects between users of two kinds of injectable contraceptives (Depo-medroxy progesterone acetate and Cyclofem).

Materials and methods: This cross-sectional descriptive study included 250 women, aged 18-40 years, using Depo-medroxy progesterone acetate (DMPA) or Cyclofem. The volunteers were examined six months after using contraceptive, and they were asked about following symptoms: weight changes, irregular bleeding, dysparounia, vaginal dryness, headache, breast pain, bone pain, and discontinuation reason. The data were analyzed by statistical methods.

Results: The important side effects of DMPA were: irregular bleeding (93.60%), weight gain (48%), bone pain (24%) and vaginal dryness (10.40%), while the side effects in the Cyclofem group were: irregular bleeding (65.60%), headache (14.4%) and breast sensitivity (20%). Bleeding pattern changes were the most important problem leading to discontinuation of both contraceptive methods in our participants.

Conclusion: The results of the study showed that the most important problem in both groups was change in bleeding pattern. Proper consulting by a trained expert reduces the high amount of discontinuation and their failure rates.

Keywords: Injectable Contraceptives, Cyclofem, Depo-Provera, Side Effects

Introduction
Since the rate of population growth increases and food sources are not sufficient, birth control is considered as one of the important solution in order to control the growth rate of population. No ideal contraceptive method has been acknowledged, yet.

For the last four decades, the researchers have strived to produce effective contraceptive methods with few side effects to provide a better birth control. Acceptability of a contraceptive method depends upon many interacting factors, like: characteristics of the method, demographic and socioeconomic variables pertaining to the population of clients (1). Injectable or implants contraception reduces the need of daily consumption (e.g. combinational pills) or depends upon sexual intercourse (e.g. condoms, etc). Today, nearly 16 million women worldwide use progestin-only or combined injectable contraceptives (2). The growing use of injectable contraceptives can be attributed to its desirable characteristic, inexpensive, not related to coitus, easy to use,
noninvasive, reversible and long-acting effect.

Depo medroxyprogesterone acetate (DMPA) was presented as a contraceptive method in the USA in 1992. The most side effect of DMPA is irregular bleeding (3,4). However, some problems as amenorrhea, headache and depression were also reported (5). Progestrone injections due to long effect can cause fertility delay after discontinuation. Therefore, other injectable medications including Cyclofem were introduced to have fewer side effects. Cyclofem is consisted of 25 mg medroxy progesterone acetate and 5 mg estradiol cypionate, being used as microcrystalline suspension by deep and intramuscular injection into the gluteal or deltoid muscles. The injection should be done in the first five days of menstrual, or after delivery before the end of sixth week. The purpose of this study was to monitor the side effects of two injectable methods (DMPA, Cyclofem) after using for six months.

Materials and methods
This cross-sectional descriptive study was conducted at Samen-Alaemeh Clinic, Kermanshah, Iran and High Risk Pregnancy Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran from July 2009 to September 2010. The study was reviewed and approved by the Ethics Committee of the Kermanshah University of Medical Sciences. Informed consent was obtained from all participants before admission to the study.

Eligible women are recruited among clients seeking family planning services at the two selected centers. Based on the previous studies, the reported complications about DMPA and Cyclofem were 24.6% and 43.5%, respectively. By assuming the study power 90% and alpha = 0.05, sample size in each group was 125 people.(6)

The inclusion criteria were women aged 18-40 years and no contraindication for using of Cyclofem and DMPA. The participants were informed to use this new method for 6 consecutive months. The exclusion criteria were: history of menstrual problem, breast feeding, pregnancy, previous injectable contraceptive, and history of other diseases, like diabetics, blood pressure, goiter, etc. About 125 women were in one-month Cyclofem injection, while 125 people were in 3-month injection of DMPA. The procedure ensured that the number of individuals allocated to each study group was equal. Participants were visited by a psychologist at the selected center, and were subjected to Beck Depression Inventory (BDI), so they were excluded from the study if they had suffered from anxiety, depression, etc. The first injection was applied during the first five days of the menstrual cycle. If the participants remained with the study for six months, they would be psychologically re-evaluated, and their mood changes would be recorded. Follow-up visits were performed every 30 days for both group. After first injection, the participants were monitored for the next six months. Information on demographic and personal characteristics were obtained from a self-administered questionnaire, completed by each participant after entering to the study. After six months, they were asked to have any problems, such as weight changes, menstrual problem (increase or decrease bleeding), amenorrhea, dyspareunia, vaginal dryness, painful sexual intercourse, bone pains, as well as other questions, like their reasons for using/not using the methods. Data were analyzed by statistic staff by required methods.

Results
The mean age in DMPA group was 32.1±5.2, while in Cyclofem group was 29.9±5.6. The mean parity in DMPA group was slightly greater than Cyclofem group, 2.39±1.24 vs. 1.5±1, respectively.

In this study, the weight gain, breast tenderness, bone pain, headache, vaginal dryness, mood changes and menstrual pattern change variables were studied as side effects of DMPA and Cyclofem methods. The most important side effects in DMPA group were menstrual cycle problems, like amenorrhea (74.4%), weight gain (48%), bone pains (24%), and vaginal dryness (10.4%). However, in Cyclofem group, the side effects were reported as menstrual problem, like bleeding reduction 47(37.6%), headache (14.4%) and breasts tenderness (20%) (Table 1).

| Side Effect               | DMPA (n=125) | Cyclofem (n=125) | p value |
|---------------------------|-------------|-----------------|---------|
| Weight gain               | 60(48%)     | 25(20%)         | <0.001  |
| Breast tenderness         | 6(4.8%)     | 25(20%)         | <0.001  |
| Bone pain                 | 30(24%)     | 18(14.4%)       | 0.054   |
| Headache                  | 2(1.6%)     | 18(14.4%)       | <0.001  |
| Vaginal dryness           | 13(10.4%)   | 5(4%)           | 0.05    |
| Mood reduction            | 16(12.8%)   | 32(25.6%)       | 0.05    |
| Spotting                  | 6(4.8%)     | 6(4.8%)         | 0.557   |
| Amenorrhea                | 93(74.4%)   | 7(5.60%)        | <0.001  |
| Reducing bleeding         | 14(11.20%)  | 47(37.60%)      | <0.001  |

Table 1: The comparison of side effects of two methods

Veisi and Zangeneh
In this study, menstrual change was the most common discontinuation reason in DMPA and Cyclofem groups (about 25% in each group). Weight gain (18.6%) and bone pain (23.25%) in DMPA group, whereas headache (10.4%) and mood changes (8%) in Cyclofem group were also reported for discontinuation reasons (Table 2).

Table 2: The discontinuation reasons in two groups

| Reason                  | DMPA (n=87 from 125) | Cyclofem (n=125) | p value |
|-------------------------|----------------------|------------------|---------|
| Menstrual change        | 32(25.6%)            | 31(24.8%)        | 0.307   |
| Weight gain             | 16(18.60%)           | 5(6.1%)          | 0.038   |
| Bone pain               | 20(23.25%)           | 0                | 0.003   |
| Mood change             | 0                    | 10(8%)           | <0.001  |
| Headache                | 1(1.16%)             | 13(10.4%)        | 0.003   |
| Breast pain             | 0                    | 4(3.2%)          | -       |
| Want to pregnancy       | 2(1.6%)              | 0                | -       |
| Vaginal dryness         | 0                    | 0                | -       |

Discussion

Rapid access to contraceptives is of great importance for women (7). Depo medroxy progesterone acetate (DMPA) is used by most of women in Iran for a long time; however, Cyclofem is newly applied for contraception. In our study, the mean age and parity in women using DMPA were more than women using Cyclofem (p=0.0008, p=0.0001, respectively). Although DMPA is considered as a long acting birth control, it has not been identified as a successful contraception because of delay in the return of fertility and limited acceptability, especially among young and low-parity women. Ruminjo et al. in their study in 2005 have showed that the mean age and parity was similar in both groups (combined and progestin-only injectable) (6). The weight gain has always been a major concern among the DMPA consumers. In current study, 48% of DMPA users gained weight after six months, but this was less in Cyclofem group. Guazzelli, Bahamondes, Bonny and Seymour have demonstrated that Cyclofem has a few effects on weight gain, but they have agreed on weight gain among DMPA users, especially among young women (8-12). Our study showed that Cyclofem could considerably lead to breast tenderness, but it was not too serious for the participants to discontinue the method. Some studies have also reported the increase of breast tenderness in Cyclofem users (13). Although, one study has reported the reduction of breast pain using Cyclofem (8). It seems that the estrogen in Cyclofem causes breast tenderness in users. According to the published studies, DMPA, as a pure progesterone, avoids the production of estrogen by suppressing ovaries and reducing blood estradiol level, leading to osteopenia (14-17). In recent study, bone density was not measured, but bone pains as pelvis, waist and legs were investigated. About 24% of the women of our study who used DMPA seriously suffered from bone pains, so stopped using it. Fortunately, osteopenia returns to young women after discontinuation of DMPA (18-19). Some studies emphasized measuring bone density for the women over 40 years old using DMPA for two years, (20). However, in our study, bone pain was less in Cyclofem users (14.4%). In similar studies, Cyclofem users experience less bone pains, so this method has no influence on bone density (8, 21). Headache was observed among the women using Cyclofem in our study, even leading to discontinuation (10.4%). Study by Guazzelli in 2007 has showed that headache is one of the discontinuation reasons of Cyclofem (8). Vaginal dryness was less investigated, but in current study, DMPA in comparison to Cyclofem significantly increased vaginal dryness in users (0.05). Vaginal dryness is not a considerable reason for discontinuation of method, and it can be explained by time restriction (six months). Mood reduction was observed more among Cyclofem users with a rate of 8% for discontinuation. It seems that Cyclofem is not tolerated by some people as oral combined pills. But in other studies, they did not observed any mood change, depression, or affective problems among young women using DMPA for 12 months (22-24). In our study, menstrual pattern change was the most important side effect in both groups.

Amenorrhea in DMPA group and bleeding reduction in Cyclofem were the most common menstrual problems. DMPA, used by millions women in all over the world, causes menstrual problems, namely amenorrhea, even through subcutaneous injection (24-26). Cyclofem, consisting of estrogen and progesterone, is used as combined pills. Although it seems to be a good method to regulate menstrual cycle, in our study, there were many complaints about menstrual problems, causing to discontinuation. According to Hall in 1998, the discontinuation of Cyclofem was high because of menstrual problems (27). Bahamondes and et al. observed that despite having estrogen, the Cyclofem doesn’t cause endometrial hyperplasia (28). Simbar and et al. provided endometrial biopsy for the DMPA and
Cyclofem users, and they observed not only reduced endometrial vasculature in both groups, but also endometrial atrophy. So, she concluded that there was no difference between Cyclofem and DMPA (29). In our study, continuation rates for DMPA and Cyclofem were 31% and 34.5%, respectively. Hajikazemi et al showed the continuance rate after six months for DMPA was about 39% (5). In Kenya, the continuance rate after 12 months for DMPA and Cyclofem were 75% and 56.5%, respectively. Also, in Mexico and China, the continuance rate after 12 months for Cyclofem were 26% and 81%, respectively (30-31). This indicates that these two methods are more applicable for other races than Iranian women (8).

Conclusion
Cyclofem and DMPA may be used as highly effective, safe and convenient methods for long term reversible contraception. The main disadvantage of both methods is menstrual irregularity. Weight gain and bone pain in DMPA users, while headache and breast tenderness in Cyclofem users were also observed as the most important side effects. We recommend using more fiber in diet to prevent weight gain. We also suggest women with migraine not to use Cyclofem. Proper consultation by a trained expert reduces the high frequency of discontinuation.

Acknowledgments
This project was supported financially by High Risk Pregnancy Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. There was not conflict of interest for this article.

References
1. Warwick DP. Culture and the management of family planning programs. Stud Fam Plann 1988; 19:1-18.
2. D’Arcangues C, Snow RC. Injectable contraceptives for women. In: Rabe T, Runnebaum B (eds). Fertility Control-Update and Trends. Springer-Verlag, Berlin 1999; 121–49.
3. Fraser IS, Dennerstein GJ. Depo-Provera use in an Australian metropolitan practice. Med J Aust 1994; 160:553-6.
4. Cromer BA, Smith RD, Blair JM, Dwyer J, Brown RT. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxy progesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 1994; 94:687-94.
5. Haji Kazemi E, Nikpoor S, haghani H. Study of reasons for discontinuation of DMPA in referred womens to IRAN university medical and health centers. RJMS 2003; 9:515-20.
6. Ruminjo JK, Skaadde-Kigondu CB, Karanja JG, Rivera R, Nasution M, Nutley T. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya. Contraception 2005; 72:138-45.
7. Westhoff C, Kems J, Morroni C, Cushman LF, Tiezzi L, Murphy PA. Quick start: novel oral contraceptive initiation method. Contraception 2002;66:141-5.
8. Guazzelli CA, Jacobucci MS, Barbieri M, Araujo FF, Moron AF. Monthly injectable contraceptive use by adolescents in Brazil: evaluation of clinical aspects. Contraception 2007; 76:45-8.
9. Bahamondes L, Diaz J, Petta C, Hall P. Weight variation in users of the once-a-month injectable contraceptive Cyclofem. Adv Contracept 1998; 14:185-92.
10. Bonny AE, Britto MT, Huang B, Succop P, Slap GB. Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxy progesterone acetate (DMPA). J Pediatr Adolesc Gynecol 2004; 17:109-15.
11. Bonny AE, Secic M, Cromer BA. A longitudinal comparison of body composition changes in adolescent girls receiving hormonal contraception. J Adolesc Health 2009; 45: 423-5.
12. Seymour RJ, Powell LC. Depo-medroxy progesterone acetate as a contraceptive. Obstet Gynecol 1970; 36:589-96.
13. Piya-Anant M, Koetsawang S, Patrasupapong N, chinhrn P, d’Arcangues C, Piaggio G, et al. Effectiveness of Cyclofem in the treatment of depotmedroxy progesterone acetate induced amenorrhea. Contraception 1998; 57:23-8.
14. Gai L, Zhang J, Zhang H, Gai P, Zhou L, Liu Y. The effect of depot medroxy progesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age. Contraception 2011; 83:218-22.
15. Kaunitz AM. Long-acting hormonal contraception: assessing impact on bone density, weight, and mood. Int J Fertil womens Med1999; 44:110-7.
16. Kuohung W, Borgatta L, Stubblefield P. Low – dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 2000; 61:77-82.
17. Williams JK. Noncontraceptive benefits of oral contraceptive use: an evidence-based approach. Int J Fertil Womens Med 2000; 45:241-7.
18. Harel Z, Johnson CC, Gold MA, Cromer B, Peterson E,
Comparison of Depo-Medroxy Progesterone Acetate (DMPA) and Cyclofem

Burkman R, et al. Recovery of bone mineral density in adolescents following the use of depot medroxy progesterone acetate contraceptive injections. Contraception 2010; 81: 281-91.

19. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraceptive use. Contraception 2008; 77: 67-76.

20. Shaarawy M, EL-Mallah SY, Seoudi S, Hassan M, Mohsen Ia. Effects of the long-term use of depot medroxy progesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contraception 2006; 74: 297-302.

21. Bahamondes L, Juliato CT, Villarreal M, Sobreira-Lima B, Simoes JA, Dos Santos Fernandes AM. Bone mineral density in users of two kinds of once-a-month combined injectable contraceptives. Contraception 2006; 74:259-63.

22. Gupta N, O’Brien R, Jacobsen LJ, Davis A, Zuckerman A, Supran S, et al. Mood changes in adolescents using depot-medroxy progesterone acetate for contraception: a prospective study. J Pediatr Adolesc Gynecol 2001; 14:71-6.

23. Westhoff C. Depot medroxy progesterone acetate contraception. Metabolic parameters and mood changes. J Reprod Med 1996; 41:401-6.

24. Westhoff C, Wieland D, Tiezzi I. Depression in users of depot-medroxy progesterone acetate. Contraception 1995; 51:351-4.

25. Hubacher D, Lopez L, steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception 2009; 80:113-8.

26. Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxy progesterone acetate subcutaneous injection 104 mg. Contraception 2006;74:234-8.

27. Hall PE. New once-a-month injectable contraceptives, with particular reference to Cyclofem/ Cyclo-Provera. Int J Gynecol Obstet 1998;62:S43-56.

28. Bahamondes L, marodiegue E, Diaz J, Trelles J, Escanhoela C, Petta C, et al. Endometrial histology in long-term users of the once-a-month injectable contraceptive Cyclofem. Adv Contracept 1999; 15:1-7.

29. Simbar M, Tehrani FR, Hashemi Z, Zham H, Fraser IS. A comparative study of Cyclofem and depot medroxyprogesterone acetate (DMPA) effects on endometrial vasculature. J Fam Plann Reprod Health Care 2007; 33:271-6.

30. Garza-Flores J, Moraks del Olmo A, Fuziwhara JL, Figueroa JG, Alonso A, Monroy J, Et al. Introduction of cyclofen once-a-month injectable contraceptive in Mexico. Contraception 1998; 58:7-12.

31. 31-Sang GW, Shao QX, Ge RS, Ge JL, Chen JK, Song S, et al. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofen and Injectable No. 1 given monthly by intramuscular injection to Chinese women. I. Contraceptive efficacy and sid effects. Contraception 1995; 51:167-83.